CN102633659B - 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 - Google Patents
一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 Download PDFInfo
- Publication number
- CN102633659B CN102633659B CN2012100420704A CN201210042070A CN102633659B CN 102633659 B CN102633659 B CN 102633659B CN 2012100420704 A CN2012100420704 A CN 2012100420704A CN 201210042070 A CN201210042070 A CN 201210042070A CN 102633659 B CN102633659 B CN 102633659B
- Authority
- CN
- China
- Prior art keywords
- trans
- amino
- aminoadamantan
- hydrochloride
- hydroxyadamantane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 23
- HMPCLMSUNVOZLH-ALPUWHEMSA-N (3s,5r)-4-aminoadamantan-1-ol Chemical compound C1C(C2)C[C@H]3C(N)[C@@H]1CC2(O)C3 HMPCLMSUNVOZLH-ALPUWHEMSA-N 0.000 title abstract description 7
- 230000002194 synthesizing effect Effects 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- HMPCLMSUNVOZLH-UHFFFAOYSA-N 4-aminoadamantan-1-ol Chemical compound C1C(C2)CC3C(N)C1CC2(O)C3 HMPCLMSUNVOZLH-UHFFFAOYSA-N 0.000 claims abstract description 18
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- KWEPNQFVPHYHHO-VSLJLWNASA-N (3s)-4-aminoadamantan-1-ol;hydrochloride Chemical compound Cl.C1C(C2)C[C@@H]3C(N)C1CC2(O)C3 KWEPNQFVPHYHHO-VSLJLWNASA-N 0.000 claims description 37
- 238000010189 synthetic method Methods 0.000 claims description 28
- 239000012043 crude product Substances 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 10
- 238000006722 reduction reaction Methods 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 5
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 6
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract 2
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000005984 hydrogenation reaction Methods 0.000 abstract 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- KWEPNQFVPHYHHO-UHFFFAOYSA-N 4-aminoadamantan-1-ol;hydrochloride Chemical compound Cl.C1C(C2)CC3C(N)C1CC2(O)C3 KWEPNQFVPHYHHO-UHFFFAOYSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- ZICQBHNGXDOVJF-UHFFFAOYSA-N diamantane Chemical compound C1C2C3CC(C4)CC2C2C4C3CC1C2 ZICQBHNGXDOVJF-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000012069 chiral reagent Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000004845 hydriding Methods 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010583 slow cooling Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- PRJMANGDYDEYMM-UHFFFAOYSA-N 2-aminoadamantan-1-ol Chemical compound C1C(C2)CC3CC1C(N)C2(O)C3 PRJMANGDYDEYMM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 229910003310 Ni-Al Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- OZBDFBJXRJWNAV-UHFFFAOYSA-N Rimantadine hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(C(N)C)C3 OZBDFBJXRJWNAV-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229960004376 rimantadine hydrochloride Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100420704A CN102633659B (zh) | 2012-02-23 | 2012-02-23 | 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100420704A CN102633659B (zh) | 2012-02-23 | 2012-02-23 | 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102633659A CN102633659A (zh) | 2012-08-15 |
CN102633659B true CN102633659B (zh) | 2013-12-04 |
Family
ID=46618258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100420704A Active CN102633659B (zh) | 2012-02-23 | 2012-02-23 | 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102633659B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101405270A (zh) * | 2006-03-22 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 作为11-β-HSD-1的吡唑类 |
CN101735080A (zh) * | 2009-12-18 | 2010-06-16 | 重庆浩康医药化工有限公司 | 反式4-氨基-1-金刚烷醇盐酸盐合成工艺 |
CN101827820A (zh) * | 2007-08-06 | 2010-09-08 | 大日本住友制药株式会社 | 氨基吡唑酰胺衍生物 |
-
2012
- 2012-02-23 CN CN2012100420704A patent/CN102633659B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101405270A (zh) * | 2006-03-22 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 作为11-β-HSD-1的吡唑类 |
CN101827820A (zh) * | 2007-08-06 | 2010-09-08 | 大日本住友制药株式会社 | 氨基吡唑酰胺衍生物 |
CN101735080A (zh) * | 2009-12-18 | 2010-06-16 | 重庆浩康医药化工有限公司 | 反式4-氨基-1-金刚烷醇盐酸盐合成工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN102633659A (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burkhardt et al. | Reductive amination with 5-ethyl-2-methylpyridine borane | |
CN106365986B (zh) | 化合物及其制备方法和在合成布瓦西坦中的用途 | |
BR112017000203B1 (pt) | processo para a produção de uma amina primária aromática | |
CN103848777B (zh) | 一种n-(3-甲氧基丙基)-4-氨基哌啶的合成方法 | |
CN102633659B (zh) | 一种反式4-氨基-1-羟基金刚烷盐酸盐的合成方法 | |
CN103304524A (zh) | 一种雷美替胺中间体的制备方法 | |
CN110105309A (zh) | 一种伏硫西汀的制备方法 | |
CN104803861B (zh) | 一种合成盐酸他喷他多的方法 | |
CN114685349B (zh) | 顺-外-二环[2.2.1]庚烷-2,3-二甲酰亚胺的制备方法 | |
CN102557967A (zh) | 一种盐酸氨溴索的制备方法 | |
CN101735080A (zh) | 反式4-氨基-1-金刚烷醇盐酸盐合成工艺 | |
CN112552184B (zh) | 一种含环丙基手性胺盐酸盐的合成方法 | |
RU2547141C1 (ru) | Способ получения n-(4-бромфенил)-n-(2-адамантил)амина (бромантана) | |
CA2750125A1 (en) | Methods for preparing s1p receptor agonists and antagonists | |
CN102617386A (zh) | 一种阿戈美拉汀的制备方法 | |
CN104610067A (zh) | 一种金刚乙胺的合成方法 | |
CN101088999A (zh) | 3-氨基奎宁二盐酸盐的合成方法 | |
CN104817476B (zh) | 一种制备非天然氨基酸的方法 | |
CN103664661B (zh) | 制备1-[2-氨基(对-甲氧基苯基)乙基]环己醇的方法 | |
CN114181077B (zh) | 一种合成氨甲环酸的方法 | |
CN106380439A (zh) | 一种水做溶剂钯炭还原法制备吲哚‑2‑甲酸 | |
KR101479986B1 (ko) | 이바브라딘 및 약제학적으로 허용되는 산과의 이의 부가염을 합성하는 새로운 방법 | |
CN102603615B (zh) | 2-丙酮基-3-甲氧基哌啶的中间体及其制备方法 | |
CN101412678A (zh) | 一种合成盐酸美金刚的方法 | |
CN106496005B (zh) | 一种4-(4-氯苯基)环己酮的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200629 Address after: No.333, Jiangnan Road, Hengdian, Dongyang City, Jinhua City, Zhejiang Province Co-patentee after: APELOA PHARMACEUTICAL Co.,Ltd. Patentee after: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Address before: 322118, 333 Jiangnan Road, Dongyang, Zhejiang, Jinhua, Hengdian Patentee before: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synthetic method of trans-4-amino-1-hydroxyadamantane hydrochloride Effective date of registration: 20210922 Granted publication date: 20131204 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330001745 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230925 Granted publication date: 20131204 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330001745 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synthesis method of trans 4-amino-1-hydroxyadamantane hydrochloride Effective date of registration: 20231007 Granted publication date: 20131204 Pledgee: Dongyang sub branch of Bank of China Ltd. Pledgor: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980059587 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |